SGLT2 inhibitor

ADA: Merck, Pfizer notch success, but late with SGLT-2 data
ADA: Merck, Pfizer notch success, but late with SGLT-2 data
BioPharma Dive
diabetes
Merck
Pfizer
SGLT2 inhibitor
Januvia
Invokana
Farxiga
Jardiance
Eli Lilly
Boehringer Ingelheim
AstraZeneca
JNJ
Flag link:
Diabetes meds from AZ, J&J and Lilly sharply cut death rates in real-world analysis
Diabetes meds from AZ, J&J and Lilly sharply cut death rates in real-world analysis
Fierce Pharma
AstraZeneca
JNJ
Eli Lilly
Boehringer Ingelheim
diabetes
Farixga
Invokana
Jardiance
SGLT2 inhibitor
Flag link:
Merck and Pfizer prep for battle with SGLT2, combo diabetes filings
Merck and Pfizer prep for battle with SGLT2, combo diabetes filings
Fierce Pharma
Merck
Pfizer
SGLT2 inhibitor
diabetes
ertugliflozin
Jardiance
Boehringer Ingelheim
Eli Lilly
JNJ
Invokana
AstraZeneca
Farxiga
Flag link:
Lilly, BI step closer to a new heart-risk marketing push on Jardiance
Lilly, BI step closer to a new heart-risk marketing push on Jardiance
Fierce Pharma Marketing
Eli Lilly
Boehringer Ingelheim
diabetes
Jardiance
SGLT2 inhibitor
Flag link:
Theracos raises $25M to take on Big Pharma in diabetes
Theracos raises $25M to take on Big Pharma in diabetes
Fierce Biotech
Theracos
diabetes
SGLT2 inhibitor
Flag link:
Bad News Type 2 Diabetics: The FDA Is Out With Another Warning
Bad News Type 2 Diabetics: The FDA Is Out With Another Warning
Motley Fool
FDA
type 2 diabetes
DPP-4 inhibitor
SGLT2 inhibitor
Flag link:
Did This Clinical Study Just Show Merck's Best-Selling Drug the Door?
Did This Clinical Study Just Show Merck's Best-Selling Drug the Door?
Motley Fool
Merck
clinical trials
Januvia
Janumet
Eli Lilly
Boehringer Ingelheim
SGLT2 inhibitor
Jardiance
Flag link:
FDA's SGLT2 warning bad news for AZ, J&J and Lilly--but could be a boon for Merck
FDA's SGLT2 warning bad news for AZ, J&J and Lilly--but could be a boon for Merck
Fierce Pharma
FDA
SGLT2 inhibitor
AstraZeneca
JNJ
Eli Lilly
Merck
diabetes
Flag link:
FDA warns on newer class of type 2 diabetes drugs
FDA warns on newer class of type 2 diabetes drugs
Yahoo/Reuters
FDA
diabetes
type 2 diabetes
AstraZeneca
Farxiga
Eli Lilly
Jardiance
Boehringer Ingelheim
JNJ
Invokana
SGLT2 inhibitor
Flag link:
J&J's Invokana fends off new SGLT2 rivals to hit $278M in Q1
J&J's Invokana fends off new SGLT2 rivals to hit $278M in Q1
Fierce Pharma Marketing
JNJ
Invokana
SGLT2 inhibitor
diabetes
Boehringer Ingelheim
Eli Lilly
Jardiance
Glyxambi
Flag link:
This is Why Diabetes Treatment Costs Are Soaring
This is Why Diabetes Treatment Costs Are Soaring
Motley Fool
diabetes
SGLT2 inhibitor
Flag link:
Islet Sciences, Inc. Confirms Issuance of U.S. Patent for Using SGLT2 Inhibitors to Treat NASH/NAFLD
Islet Sciences, Inc. Confirms Issuance of U.S. Patent for Using SGLT2 Inhibitors to Treat NASH/NAFLD
Yahoo
patents
Islet Sciences
SGLT2 inhibitor
NASH
NAFLD
Flag link:
Eli Lilly and BI's Jardiance hits shelves
Eli Lilly and BI's Jardiance hits shelves
Medical Marketing and Media
Eli Lilly
Jardiance
Boehringer Ingelheim
diabetes
SGLT2 inhibitor
Flag link:
The Diabetes Pipeline With a Clog
The Diabetes Pipeline With a Clog
Motley Fool
diabetes
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
JNJ
SGLT2 inhibitor
Forxiga
Invokana
empagliflozin
Flag link:
What Will Type 2 Diabetes Treatments Look Like in 5 Years?
What Will Type 2 Diabetes Treatments Look Like in 5 Years?
Motley Fool
diabetes
Merck
SGLT2 inhibitor
Bristol-Myers Squibb
AstraZeneca
JNJ
Array Biopharma
Januvia
Amgen
Forixga
GKAs
Flag link:
Bristol-Myers, AstraZeneca Type 2 diabetes pill gets first major approval, in European Union
Bristol-Myers, AstraZeneca Type 2 diabetes pill gets first major approval, in European Union
Yahoo/AP
diabetes
Bristol-Myers Squibb
AstraZeneca
Europe
SGLT2 inhibitor
Forxiga
Flag link:
Who Will Pioneer the New Diabetes Market?
Who Will Pioneer the New Diabetes Market?
Motley Fool
diabetes
JNJ
Merck
Bristol-Myers Squibb
AstraZeneca
SGLT2 inhibitor
Flag link:
Lilly Backs Broad Diabetes Range to Challenge Rivals
Lilly Backs Broad Diabetes Range to Challenge Rivals
Bloomberg
Eli Lilly
diabetes
Boehringer Ingelheim
Amylin
LY2605541
GLP-1 agonist
SGLT2 inhibitor
Flag link: